PR Newswire BiotechOriginal article
AnnJi Pharmaceutical avanza AJ201 al ensayo ROMA-KD para la atrofia muscular espinobulbar
Phase 3AJ201Positive
AI Analysis
Summary
AnnJi Pharmaceutical advances AJ201 (rosolutamida), an oral small molecule, into the Phase 3 ROMA-KD pivotal trial for spinal bulbar muscular atrophy (SBMA), described as the only known investigational therapy for this condition in Phase 3 development globally.
Clinical Trial Data
Phase
3
Importance:7/10
Sentiment:
0.70
Phase 3SBMASmall moleculeOral administrationPivotal trialRare disease
Read the original article
Published by PR Newswire Biotech on October 6, 2026 4:44 AM